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Abstract
We report a 52-year-old patient who developed B-cell non-Hodgkin’s lymphoma subsequent to sarcoidosis.
Sarcoidosis was diagnosed 16 years ago and remained asymptomatic for 14 years after steroid treatment. She
presented with new symptoms of arthralgia, photosensitivity, butterfly erythema, autoimmune antibodies (ANA,
chromatin positivity) associated with progression of the known left upper lobe lesion on the chest X-ray suggesting
primary autoimmune disease (systemic lupus erythematosus). As steroid treatment was not effective, we started
bolus cyclophosphamide therapy after which progression was seen on the chest X-ray. Computed tomography
(CT)-guided needle biopsy confirmed malignancy of indefinable origin. Despite of the well-known
fluorodeoxyglucose (FDG) avidity in active sarcoidosis, a FDG-positron emission tomography (PET) scan was
performed to stage the primary tumour. Intensive FDG uptake was detected in the affected lung segment, with
moderate uptake in mediastinal lymph nodes. The patient underwent left upper lobectomy. The histology showed
pulmonary mucosa-associated lymphoma (bronchus-associated lymphoid tissue (BALT) lymphoma) in the lung
tissue, while only sarcoidosis was present in the mediastinal lymph nodes. Bone marrow biopsy was negative.
The association between sarcoidosis and lymphoma is known as sarcoidosis lymphoma syndrome, which is a rare
disease. PET-CT was helpful in the differentiation of sarcoidosis and malignancy in this patient. It is important to be
aware of the risk of lymphoma in sarcoidosis and FDG-PET, used for adequate purpose, can help the diagnosis.
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Background
Sarcoidosis is a chronic granulomatous inflammatory
multisystem disorder of unknown origin. The associ-
ation between sarcoidosis and malignancy - particularly
lymphoproliferative disease, such as non-Hodgkin’s
lymphoma - has been previously described [1-3]. In sar-
coidosis lymphoma syndrome, sarcoidosis is followed by
the development of the lymphoproliferative disorder
[4]. Higher fluorodeoxyglucose (FDG)-uptake may be
seen in both diseases; therefore, positron emission
tomography-computed tomography (PET-CT) cannot
exclude or prove the presence of malignancy in sarcoid-
osis patients. In our case report of sarcoidosis lymph-
oma syndrome, we demonstrate how PET-CT could
help within the decision making process.
Case presentation
The 52-year-old female patient first presented in 1992
with erythema nodosum, alopecia and a dry cough. Chest
X-ray and computed tomography (CT) showed bilateral
hilar lymphadenopathy and lung parenchyma involve-
ment. Histology confirmed sarcoidosis, which was treated
with systemic steroids for six months, after which per-
sisting diabetes mellitus developed. After 14 asymptomatic
years without immunosuppressive therapy, she was re-
ferred to our department with symptoms of dry cough,
snoring and mild anaemia. On the chest X-ray, progres-
sion of the known left upper lobe lesion was noted
(Figure 1). As primarily progression of sarcoidosis was
suspected, steroid treatment was restarted. During the im-
munosuppressive therapy arthralgia, butterfly erythema,
photosensitivity appeared, associated with anti-nuclear
and anti-chromatin antibody positivity. A lung function
test revealed decreased diffusion capacity of carbon
monoxide (CO). According to the American College of
Rheumatology’s criteria, an additional diagnosis of systemic
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lupus erythematosus (SLE) was established. Due to inef-
fective response to steroid treatment, bolus cyclophos-
phamide (500 mg/m2 monthly) therapy was instituted.
Repeated chest X-ray showed rapid and significant
worsening of the left upper lobe lesion following the
first dose (Figure 2). Beside the left upper lobe lesion, en-
larged mediastinal lymph nodes and a small nodular lesion
in the left lower lobe (segment 10) were noted on the chest
CT. Histology of the transbronchial biopsy from the left
upper lobe showed nonspecific lymphocytic inflammation.
CT-guided needle aspiration of the left upper lobe lesion
was performed to get proper diagnosis (Figure 3). Cytology
confirmed malignancy of indefinable, but possible renal ori-
gin. Abdominal ultrasound and CT scan were negative.
To localize the primary tumour and its stage, FDG-
PET-CT scan was made, knowing that active sarcoidosis
is associated with increased FDG uptake. Intensive FDG
uptake was detected in the affected lung segment, with
only moderate uptake in mediastinal lymph nodes
(Figure 4). As the nodule in the left lower lobe showed
moderate FDG uptake similar to mediastinal lymph nodes,
it was suggested to represent sarcoidosis. Taking into con-
sideration the very intensive FDG uptake and cytology
confirmed malignancy of the left upper lobe, our surgical
team came to the decision of performing a left upper lob-
ectomy and extensive lymph node sampling.
Postoperative histology showed pulmonary mucosa-
associated lymphoma (bronchus associated lymphoid
tissue (BALT) lymphoma) in the left upper lobe lung tis-
sue, while only sarcoidosis was present in the mediastinal
lymph nodes. Immunophenotyping demonstrated a B cell
lineage phenotype: CD20, BCL2 and lambda light chain
positivity on the cell surface, with CD10 and CD5 negativ-
ity (Figure 5). The tumour was confined only to the lung
parenchyma of the left upper lobe; haematological exami-
nations, including bone marrow biopsy, were negative,
confirming the diagnosis of stage I BALT lymphoma. After
surgery the patient received only respiratory rehabilitation.
Three-year follow-up with regular chest-abdominal CT
scans showed no progression or recurrence of the diseases
(Figures 6 and 7).
Sarcoidosis is a multisystem granulomatous disorder of
uncertain origin. The diagnosis of sarcoidosis is based on
clinical, radiological, biochemical and histological findings.
These findings are erythema nodosum, lymphopenia,
hypergammaglobulinemia, anergy, hypercalcemia and ele-
vated angiotensin-converting enzyme. The non-caseating
granulomas are B-cell negative [1]. The results should be
carefully interpreted, because sarcoid-like granulomas can
be found in many other disorders, such as chronic inflam-
matory, infectious and neoplastic diseases [2]. Incidence is
influenced by age, race and geographical location. The
subacute form diagnosed in most patients under the age
of 30 affects mainly intrathoracic organs and the duration
of the disease is generally less than two years. The chronic
form begins more often over the age of 40 and might in-
volve extrathoracic organs [1].
Brincker and Wilbek have matched all patients who had
been diagnosed with respiratory sarcoidosis during the
period 1962 to 1971 against the data of the Cancer Regis-
try. About 1.5 times higher incidence of cancer was seen
in sarcoidosis patients. Lung cancer occurred 3 times and
malignant lymphoma 11.5 times more frequently than in
the control population [3]. In a later study, Brincker found
three features of malignancies following sarcoidosis based
on the analysis of 29 case reports in the literature [1]: the
median age of the patients was 41 years at the diagnosis of
sarcoidosis, which indicates a late onset, and is more often
associated with a chronic type [2]. Lymphoproliferative
disease (LD) has occurred with a median interval of 24
months after the diagnosis of sarcoidosis [3]. Hodgkin’s
Figure 1 Chest X-ray of the patient. After 14 asymptomatic years,
new symptoms occurred. The chest X-ray showed progression of
the known left upper lobe lesion.
Figure 2 Repeat chest X-ray. Repeat chest X-ray showed rapid and
significant worsening of the left upper lobe lesion.
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disease was diagnosed more frequently than other types of
lymphomas. Further analysis of 17 cases revealed that LD
developed 5.5 times more frequently than expected, which
may suggest that the chronic active type of sarcoidosis is a
predisposing factor for LD. Brincker introduced the term
sarcoidosis lymphoma syndrome for this specific condi-
tion [4]. In a retrospective cohort study Askling and his
colleagues assessed the risk for malignancy in sarcoidosis.
They linked a sarcoidosis incidence study (Uppsala
Cohort) and patients identified with sarcoidosis in the
Swedish Inpatient Register to population-based registers
(Cancer Register, Register of Causes of Death, Register of
Total Population). Significantly increased risk for malig-
nant diseases including lung, stomach, small intestine and
liver, for melanoma and non-melanoma skin cancer, non-
Hodgkin’s lymphoma (NHL) and leukaemia was noted.
For non-Hodgkin’s lymphoma the risk was nearly doubled
five to nine years after the diagnosis of sarcoidosis [5].
There are many theories explaining the possible rela-
tionship of this association. The changes in the number
and the functions of immune cells in sarcoidosis are well
described, suggesting dysfunction in the immunoregula-
tory pathways leading to granuloma formation. A clone
may escape in an environment with defective T suppressor
Figure 3 Computed tomography (CT) guided needle biopsy of the left upper lobe lesion.
Figure 4 Fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan.
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cells regulation resulting in the development of lymphoid
malignancy. In this context, chronic sarcoidosis represents
a more prolonged and more severe form of the disease.
Steroid treatment, by further compromising the immune
system, might be an additional predisposing factor [2].
There are some cases in which LD developed subsequent
to sarcoidosis [6,7], but only a few case reports present
malignancy preceding sarcoidosis. Suen et al. described
six patients who developed malignancy first, followed by
the diagnosis of sarcoidosis. The median interval between
the diagnoses of the two diseases was only nine months
[8]. There are also some patients with NHL, who devel-
oped sarcoidosis subsequent to the diagnosis of LD.
Kornacker et al. reported two cases, where NHL was iden-
tified and treated for 3 and 10 months before the diagnosis
of sarcoidosis. They proposed that sarcoidosis had been
triggered by immunological disturbance induced by
chemotherapy or associated with the lymphoma. They
Figure 5 Immunophenotyping of pulmonary mucosa-associated lymphoma. B cell lineage phenotype was demonstrated: CD20, BCL2 and
lambda light chain positivity on the cell surface with CD10 and CD5 negativity.
Figure 6 Repeat chest computed tomography (CT) scan one
year after surgery. One-year follow-up showed no progression of
the diseases.
Figure 7 Repeat chest X-ray one year after surgery. One-year
follow-up showed no progression of the diseases.
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supposed an infectious agent, which could have spread
due to the immunosuppression (caused by chemotherapy)
resulting in granuloma formation. Alternatively antineo-
plastic therapy might have reduced suppressor T cells
leading to lymphocyte activation observed in sarcoidosis
[9]. Sybert et al. reported a patient with osteosarcoma
who developed granulomatous lymphadenopathy and
multiple pulmonary nodules confirmed as sarcoidosis
following cessation of treatment. They suggested that
immunosuppression inhibited the development of sarcoid-
osis, which became symptomatic when chemotherapy was
terminated [10].
FDG-PET is a sensitive method for the staging of sev-
eral malignancies, the underlying biological principle is
based on the Warburg effect [11]. FDG is transported
into cells by glucose transporter GLUT-1 and is metabo-
lized to FDG-6-phosphate and trapped [12]. The degree
of the FDG uptake depends on the number of trans-
porters and on the metabolic rate. Physiological activity
is detected in the brain, myocardium and genitourinary
tract. Due to increased metabolism, malignant tissues
typically demonstrate higher FDG uptake than benign le-
sions and normal tissues. In patients with sarcoidosis,
FDG-PET could be used for monitoring the response to
treatment because FDG uptake correlates with disease
activity but is not useful for initial diagnosis as it could
be misinterpreted as a malignancy [13].
In a study with 21 patients, Bae et al. found that BALT
lymphomas show heterogeneous but identifiable FDG up-
take on PET scans [14]. They analyzed the role of FDG-
PET for staging and follow-up of patients with extranodal
marginal zone mucosa (mucosa associated lymphoid tis-
sue, MALT) lymphomas. A total of 42 patient scans and
clinical information were reviewed. MALT lymphomas
have high FDG avidity and PET scan is usable for detec-
tion of areas of transformation and for staging. In 34 of
the 42 patients, there was FDG avidity, which demon-
strated that FDG-PET scan is a possible diagnostic tool for
the detection of MALT lymphoma in the majority of
patients. Eleven patients who had BALT lymphoma in
their lung all showed focal FDG uptake on PET scans. The
authors suggested that with the advance and spread of the
technology, its role in cancer - especially in MALT lymph-
omas - will expand and will lead to more accurate staging
and better management of the disease [15].
According to the current literature, our patient had
chronic sarcoidosis and had been treated with systemic
steroids. The development of autoimmunity (SLE) and
its treatment with cyclophosphamide induced changes in
the slow growing tumour. This is in line with the theory
that abnormal immune function contributes to the de-
velopment of LD, and that immunosuppressive therapy
may enhance it [16,17]. The development of lymphoma
presented over a decade.
Conclusions
According to previous observations, sarcoidosis predis-
poses for lymphoid malignancies. Sarcoidosis and lymph-
oma both can cause increased FDG uptake in mediastinal
lymph nodes, thus FDG-PET-CT cannot prevent the need
for histological verification [18]. In our patient suffering
from sarcoidosis, malignancy was only confirmed by cy-
tology so FDG-PET-CT was an important diagnostic tool
in the further decision-making process. The progression
of the lung lesion, later confirmed as BALT lymphoma,
occured following steroid and cyclophosphamide treat-
ment (both agents used in the treatment of lymphomas),
which was retrospectively interesting and unexpected. Fu-
ture studies are needed to assess the full potential of
FDG-PET-CT in the diagnosis of sarcoidosis lymphoma
syndrome.
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